Affiliation:
1. Tver State Medical University
2. LLC “Surgery”
Abstract
Introduction. Sulodexide is a polymer, the structure of which includes unbranched polysaccharide chains formed by repeating a particular disaccharide unit. This drug was isolated from the endothelium of the pig, and it appeared on the pharmaceutical market in 1974. Sulodexide contains ≈ 80% heparan sulfate (also known as fast-acting heparin) and 20% dermatan sulfate. This drug is produced from the more sulfated waste heparinoids. During production, heparin is chemically decomposed and transformed into the clinical drug Sulodexide. Aim. To estimate the possibilities and prospects of using the drug Sulodexid in the treatment of various diseases. Materials and methods. During this study, we analyzed relevant sources of domestic and foreign literature on the use of the drug Sulodexid in various pathologies. Sources of information included publications from the Russian scientific electronic library integrated with the Russian Science Citation Index, the Medline database, Scopus, Science Direct, Cyberleninka.ru, and the New England Journal of Medicine. Results and discussion. The pharmacological action of the drug is not limited to anticoagulant action, it also has antiaggregant and angioprotective effects. The drug has found application in various fields of medicine, such as pediatrics, surgery, therapy, endocrinology, neurology and proctology. The possibility of wide application is also promoted by the availability of different forms and methods of administration of this drug: intramuscular, infusion and oral, which allows prescribing the drug both in inpatient and outpatient settings. In contrast to other anticoagulants the drug has the most favorable action, since the risk of bleeding is low. Conclusion. In spite of a sufficiently wide use of the study drug in clinical practice, inclusion in the national clinical guidelines, other effects of the drug require further studies. It is difficult to make a conclusion about the efficacy of the drug in the treatment of some diseases, but with further studies, there is a chance of including it in the therapy of different pathological conditions.
Reference57 articles.
1. Carroll B.J., Piazza G., Goldhaber S.Z. Expand Sulodexide in venous disease. J Thromb Haemost. 2019;17(1):31–38. https://doi.org/10.1111/jth.14324.
2. Dou H., Song A., Jia S., Zhang L. Chapter Four – Heparinoids Danaparoid and Sulodexide as clinically used drugs. Prog Mol Biol Transl Sci. 2019;163:55–74. https://doi.org/10.1016/bs.pmbts.2019.02.00.
3. Munari A.C., Cantu S.O., Huet N.E., Alfaro M.A. Could Sulodexide be Helpful in COVID-19. MedDocs Publishers. 2021;946(3). Available at: https://annals-of-cardiology-and-vascular-medicine/could-sulodexide-behelpful-in-COVID-19.pdf.
4. Gonzalez-Ochoa A.J., Raffetto J.D., Hernández A.G., Zavala N., Gutiérrez O., Vargas A., Loustaunau J. Sulodexide in the treatment of patients with early stages of COVID-19 a randomized controlled trial. Thromb Haemost. 2021;121(7):944–954. https://doi.org/10.1055/a-1414-5216.
5. Li T., Liu X., Zhao Z., Ni L., Liu C. Sulodexide recovers endothelial function through reconstructing glycocalyx in the balloon-injury rat carotid artery model. Oncotarget. 2017;8(2):91351. https://doi.org/10.18632/oncotarget.20518.